Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Nadavaluru Reddy

Clinical Cardiac Electrophysiology Springfield, MA Medical Doctor

NPI 1689852691 CMS profile 753196

300 Stafford St Ste 154, Springfield, MA 01104

Open in the dashboard

General payments

$69,167

594 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Nadavaluru Reddy of Springfield, MA is reported in the CMS Open Payments database as having received $69,167 across 594 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 82nd percentile of Clinical Cardiac Electrophysiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $11,402 84
2024 General $6,183 73
2023 General $8,292 98
2022 General $12,575 114
2021 General $12,984 91
2020 General $8,957 58
2019 General $8,774 76

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Nadavaluru Reddy
  • Clinical Cardiac Electrophysiology median
  • Middle half of Clinical Cardiac Electrophysiology
  • National median

In program year 2025, general payments to Nadavaluru Reddy were reported at $11,402. Among 3,064 Clinical Cardiac Electrophysiology profiles paid that year, the median was $2,462 and the middle half received between $733 and $7,710.

Show as a table
Year Nadavaluru Reddy Clinical Cardiac Electrophysiology median Middle half National median
2019 $8,774 $2,361 $585–$8,260 $163
2020 $8,957 $993 $247–$4,351 $114
2021 $12,984 $1,185 $326–$4,739 $132
2022 $12,575 $2,073 $554–$6,789 $149
2023 $8,292 $2,568 $759–$8,159 $160
2024 $6,183 $2,557 $703–$7,403 $164
2025 $11,402 $2,462 $733–$7,710 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Biotronik Inc. $25,432 132 payments
  2. Abbott Laboratories $19,083 112 payments
  3. Medtronic, Inc. $13,660 166 payments
  4. Medtronic Vascular, Inc. $3,478 56 payments
  5. Boston Scientific Corporation $2,045 30 payments
  6. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $1,696 4 payments
  7. Biosense Webster, Inc. $1,014 9 payments
  8. AstraZeneca Pharmaceuticals LP $802 7 payments
  9. Pfizer Inc. $556 35 payments
  10. Janssen Pharmaceuticals, Inc $532 14 payments
  11. Other $869 29 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $33,544 522 payments
  2. Travel and Lodging $22,118 58 payments
  3. Consulting Fee $8,628 9 payments
  4. Compensation for serving as faculty or as a speaker for a medical education program $3,200 2 payments
  5. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $1,500 2 payments
  6. Education $177 1 payment
Products named General payments · program years 2019–2025
  1. Edora $9,372 33 payments
  2. Acticor $9,372 33 payments
  3. Rivacor $9,334 32 payments
  4. BioMonitor $7,891 27 payments
  5. Solia $7,873 26 payments
  6. Micra $5,488 64 payments
  7. Sentus $5,336 8 payments
  8. Plexa $5,336 8 payments
  9. Acticor 7 VR-T DX $4,463 14 payments
  10. Edora 8 DR-T $3,867 3 payments
  11. Other $37,597 384 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 20 drugs

Part D claims

607

Median for Clinical Cardiac Electrophysiology: 1,090

Drug cost

$158,312

Median for Clinical Cardiac Electrophysiology: $354,841

Branded share of claims

38.6%

Median for Clinical Cardiac Electrophysiology: 38.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 75 $100,804
Xarelto Rivaroxaban Brand 16 $25,261
Entresto Sacubitril/Valsartan Brand 24 $22,667
Amiodarone Hcl Generic 48 $2,988
Metoprolol Succinate Generic 78 $1,521
Diltiazem 24hr Er (Cd) Diltiazem Hcl Brand 35 $960
Flecainide Acetate Generic 15 $805
Clopidogrel Clopidogrel Bisulfate Brand 68 $692
Sotalol Sotalol Hcl Brand 16 $466
Losartan Potassium Generic 19 $403

The 10 drugs with the highest cost, of 20 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,573 Part D prescribers listed as Clinical Cardiac Electrophysiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 66 billing codes

Paid by Medicare

$270,711

Medicare's payments for the services billed

Medicare patients

1,485

Average age 76

Services billed

5,218

746 women, 739 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Atrial fibrillation 51%
Arthritis 49%
Heart failure 44%
Ischemic heart disease 43%
Chronic kidney disease 40%
Diabetes 36%
COPD 31%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 6 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ENTRESTO
  • Novartis Pharmaceuticals Corporation $126
$126 24 —
XARELTO
  • Janssen Pharmaceuticals, Inc $109
$109 16 —
ELIQUIS
  • PFIZER INC. $108
$108 75 —
VYNDAQEL
  • PFIZER INC. $48
$48 — —
PAXLOVID
  • PFIZER INC. $28
$28 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 6 in the dashboard with a free account

Records

594 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Cardiac Electrophysiology in Massachusetts

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record